Search Results - "Ocio, E"

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma by Paiva, B, Azpilikueta, A, Puig, N, Ocio, E M, Sharma, R, Oyajobi, B O, Labiano, S, San-Segundo, L, Rodriguez, A, Aires-Mejia, I, Rodriguez, I, Escalante, F, de Coca, A G, Barez, A, San Miguel, J F, Melero, I

Get full text

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects by Hurchla, M A, Garcia-Gomez, A, Hornick, M C, Ocio, E M, Li, A, Blanco, J F, Collins, L, Kirk, C J, Piwnica-Worms, D, Vij, R, Tomasson, M H, Pandiella, A, San Miguel, J F, Garayoa, M, Weilbaecher, K N

“…Proteasome inhibitors (PIs), namely bortezomib, have become a cornerstone therapy for multiple myeloma (MM), potently reducing tumor burden and inhibiting…”
Get full text

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia by Jiménez, C, Sebastián, E, Chillón, M C, Giraldo, P, Mariano Hernández, J, Escalante, F, González-López, T J, Aguilera, C, de Coca, A G, Murillo, I, Alcoceba, M, Balanzategui, A, Sarasquete, M E, Corral, R, Marín, L A, Paiva, B, Ocio, E M, Gutiérrez, N C, González, M, San Miguel, J F, García-Sanz, R

“…We evaluated the MYD88 L265P mutation in Waldenström’s macroglobulinemia (WM) and B-cell lymphoproliferative disorders by specific polymerase chain reaction…”
Get full text

Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification by Paiva, B, Montes, M C, García-Sanz, R, Ocio, E M, Alonso, J, de las Heras, N, Escalante, F, Cuello, R, de Coca, A G, Galende, J, Hernández, J, Sierra, M, Martin, A, Pardal, E, Bárez, A, Alonso, J, Suarez, L, González-López, T J, Perez, J J, Orfao, A, Vidríales, M-B, San Miguel, J F

“…Although multiparameter flow cytometry (MFC) has demonstrated clinical relevance in monoclonal gammopathy of undetermined significance (MGUS)/myeloma,…”
Get full text

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair by Maiso, P, Colado, E, Ocio, E M, Garayoa, M, Martín, J, Atadja, P, Pandiella, A, San-Miguel, J F

“…Acute myeloid leukemia (AML) is a clonal disorder characterized by the accumulation of myeloid blasts in the bone marrow. Here, we report the effects of the…”
Get full text

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel by Caers, J, Paiva, B, Zamagni, E, Leleu, X, Bladé, J, Kristinsson, S Y, Touzeau, C, Abildgaard, N, Terpos, E, Heusschen, R, Ocio, E, Delforge, M, Sezer, O, Beksac, M, Ludwig, H, Merlini, G, Moreau, P, Zweegman, S, Engelhardt, M, Rosiñol, L

“…Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary…”
Get full text

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone by Ocio, E M, Fernández-Lázaro, D, San-Segundo, L, López-Corral, L, Corchete, L A, Gutiérrez, N C, Garayoa, M, Paíno, T, García-Gómez, A, Delgado, M, Montero, J C, Díaz-Rodríguez, E, Mateos, M V, Pandiella, A, Couto, S, Wang, M, Bjorklund, C C, San-Miguel, J F

“…The development of resistance to therapy is unavoidable in the history of multiple myeloma patients. Therefore, the study of its characteristics and mechanisms…”
Get full text

Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals by GUTIERREZ, N. C, OCIO, E. M, DE LAS RIVAS, J, MAISO, P, DELGADO, M, FERMINAN, E, ARCOS, M. J, SANCHEZ, M. L, HERNANDEZ, J. M, SAN MIGUEL, J. F

“…The tumoral clone of Waldenström's macroglobulinemia (WM) shows a wide morphological heterogeneity, which ranges from B lymphocytes (BL) to plasma cells (PC)…”
Get full text

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential by Paíno, T, Paiva, B, Sayagués, J M, Mota, I, Carvalheiro, T, Corchete, L A, Aires-Mejía, I, Pérez, J J, Sanchez, M L, Barcena, P, Ocio, E M, San-Segundo, L, Sarasquete, M E, García-Sanz, R, Vidriales, M-B, Oriol, A, Hernández, M-T, Echeveste, M-A, Paiva, A, Blade, J, Lahuerta, J-J, Orfao, A, Mateos, M-V, Gutiérrez, N C, San-Miguel, J F

“…Knowledge about clonal diversity and selection is critical to understand multiple myeloma (MM) pathogenesis, chemoresistance and progression. If targeted…”
Get full text

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control by Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, Miguel, J F San

“…Achieving complete remission (CR) in multiple myeloma (MM) translates into extended survival, but two subgroups of patients fall outside this paradigm: cases…”
Get full text

The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes by Tabera, Soraya, Perez-Simon, Jose A, Diez-Campelo, Maria, Sanchez-Abarca, Luis I, Blanco, Belen, Lopez, Antonio, Benito, Ana, Ocio, Enrique, Sanchez-Guijo, Fermin M, Canizo, Consuelo, San Miguel, Jesus F

“…Servicio de Hematología, Hospital Clínico Universitario and Centro de Investigación del Cáncer (CIC); Servicio de Citometría, Universidad de Salamanca, Centro…”
Get full text

6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis by Ocio, E. M., Schop, R. F. J., Gonzalez, B., Van Wier, S. A., Hernandez‐Rivas, J. M., Gutierrez, N. C., Garcia‐Sanz, R., Moro, M. J., Aguilera, C., Hernandez, J., Xu, R., Greipp, P. R., Dispenzieri, A., Jalal, S. M., Lacy, M. Q., Gonzalez‐Paz, N., Gertz, M. A., San Miguel, J. F., Fonseca, R.

“…Summary Fluorescence in situ hybridisation (FISH) is an effective technique for the cytogenetic analysis of Waldenström macroglobulinemia (WM), but the…”
Get full text

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma by González-Calle, V, Dávila, J, Escalante, F, de Coca, A G, Aguilera, C, López, R, Bárez, A, Alonso, J M, Hernández, R, Hernández, J M, de la Fuente, P, Puig, N, Ocio, E M, Gutiérrez, N C, García-Sanz, R, Mateos, M V

“…The diagnosis of smoldering multiple myeloma (SMM) includes patients with a heterogeneous risk of progression to active multiple myeloma (MM): some patients…”
Get full text

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) by Ocio, E M, Richardson, P G, Rajkumar, S V, Palumbo, A, Mateos, M V, Orlowski, R, Kumar, S, Usmani, S, Roodman, D, Niesvizky, R, Einsele, H, Anderson, K C, Dimopoulos, M A, Avet-Loiseau, H, Mellqvist, U-H, Turesson, I, Merlini, G, Schots, R, McCarthy, P, Bergsagel, L, Chim, C S, Lahuerta, J J, Shah, J, Reiman, A, Mikhael, J, Zweegman, S, Lonial, S, Comenzo, R, Chng, W J, Moreau, P, Sonneveld, P, Ludwig, H, Durie, B G M, Miguel, J F S

“…Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs…”
Get full text

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO‐HSCT FOR ADVERSE‐CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA by Cerezo‐Martin, J. M., Avendaño, A., Fernandez‐Luis, S., Calvo, J. A., Ocio, E., Colorado, M., Bermudez, A.

Get full text

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma by Fernández de Larrea, C, Dávila, J, Isola, I, Ocio, E M, Rosiñol, L, García-Sanz, R, Cibeira, M T, Tovar, N, Rovira, M, Mateos, M V, Miguel, J S, Bladé, J

“…The response evaluation after autologous stem-cell transplantation (ASCT) is usually performed at day +100 in patients with multiple myeloma (MM). A recent…”
Get full text

P960: HEALTH‐RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL‐LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by Delforge, M., Moreau, P., Einsele, H., De Stefano, V., Lindsey‐Hill, J., Vincent, L., Mangiacavalli, S., Perrot, A., Ocio, E., Seldam, S., ’. Groen‐Damen, E. I., Semerjian, M., Strulev, V., Schecter, J. M., Roccia, T., Gries, K. S., Nesheiwat, T., Wapenaar, R., Mateos, M.‐V., Weisel, K.

Get full text

Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis by RAMIREZ, J. M, OCIO, E. M, SAN MIGUEL, J. F, PANDIELLA, A

“…Multiple myeloma (MM) is a malignancy of terminally differentiated B lymphocytes, characterized by accumulation of a monotypic plasma cell population in the…”
Get full text

Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes by Hernández, J M, Castilla, C, Gutiérrez, N C, Isidro, I M, Delgado, M, de las Rivas, J, Fermiñán, E, García, J L, Ocio, E M, del Cañizo, M C, San Miguel, J F

Get full text

Amiloride induces potent antitumoral activity in multiple myeloma through the reactivation of mutant p53 by Rojas, E, Misiewicz-Krzeminska, I, García, S.H, Paíno, T, Corchete, L.A, Isidro, I, Mateos, M.V, Ocio, E, Gutiérrez, N.C

Get full text